- Home
- KTTA
as 12-18-2024 11:38am EST
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
| Founded: | 2020 | Country: | United States |
| Employees: | 8 | City: | VENICE |
| Market Cap: | 3.4M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 57.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.57 - $9.40 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pasithea Therapeutics Corp. News
KTTA Breaking Stock News: Dive into KTTA Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
GlobeNewswire
3 months ago
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
MT Newswires
3 months ago
Sector Update: Health Care Stocks Mixed Late Afternoon
MT Newswires
3 months ago
Sector Update: Health Care
MT Newswires
3 months ago
Top Midday Gainers
Benzinga
3 months ago
Why Is Pasithea Therapeutics Stock Surging On Thursday?
MT Newswires
3 months ago
Top Premarket Gainers
MT Newswires
3 months ago
Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell
Compare KTTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KTTA Pasithea Therapeutics Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.